Test Price
2,800 AED✅ Home Collection Available
ATP13A2 (PARK9) Gene Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين ATP13A2 (PARK9) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary – UAE Leading Genetic Test for Early-Onset Parkinson Disease & Kufor-Rakeb Syndrome
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited Next-Generation Sequencing.
- Premium Logistics: Paid Hospital-Grade Home Collection with ISO Certified Cold-Chain transport and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Interpretation by a DHA-Licensed Neurologist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
فحص جيني متقدم لتحليل جين ATP13A2 المرتبط بداء باركنسون المبكر ومتلازمة كوفور-ركيب، بدقة تشخيصية 99.9% وخصوصية تامة بموجب القانون الإماراتي.
Overview of ATP13A2 (PARK9) Gene Sequencing
This comprehensive NGS-based test examines the entire coding region and flanking intronic boundaries of the ATP13A2 gene (PARK9), associated with autosomal recessive Kufor-Rakeb syndrome and early-onset Parkinson disease. By identifying pathogenic variants, the results empower precise clinical management, prognostication, and informed family planning in the UAE.
يغطي هذا الفحص تسلسل الجين الكامل لتحديد الطفرات المسببة لداء باركنسون المبكر ومتلازمة كوفور-ركيب، مما يساعد في التخطيط العلاجي والاستشارة الوراثية.
| Feature | Our ATP13A2 NGS Test | Closest Alternative (Single‑Gene Sanger / Exome) |
|---|---|---|
| Precision & Coverage | 100% exon coverage with deep intronic variant analysis, CNV detection capability | Limited to targeted exons or may miss deep intronic mutations; variable CNV detection |
| Methodology | Next-Generation Sequencing (NGS) on Illumina® platform, verified by MLPA if indicated | Sanger sequencing of selected regions or whole-exome sequencing with lower read depth |
| Turnaround Time | 3 to 4 Weeks | Typically 4–8 Weeks |
| Clinical Utility | Gold standard for diagnostic confirmation of ATP13A2‑related Parkinson and Kufor‑Rakeb syndrome | May require reflex testing, delaying definitive diagnosis |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY (DHA License: 61713011) notes:
“This ATP13A2 NGS test is a vital tool for patients with early-onset parkinsonism or a family history of Kufor‑Rakeb syndrome. However, genetic results must always be interpreted in the context of a thorough neurological evaluation. A negative report does not exclude other genetic or neurodegenerative causes of parkinsonism, and any treatment adjustments should be made under specialist guidance.”
Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Changes to dopaminergic therapy based solely on genetic results can precipitate serious adverse events.
Safety Exclusion Criteria & Urgent Care Red Flags
- Exclusion: Active systemic infection, severe immunosuppression (risk of sample degradation); individuals unable to provide informed consent must have legal guardian authorization as per UAE CDS Law 2026.
- ER Red Flags: If you experience a sudden, severe increase in Parkinsonian rigidity, recurrent falls, loss of consciousness, or new-onset seizures while awaiting results, seek emergency medical care immediately.
Frequently Asked Questions & Clinical Guidance
1. What is the ATP13A2 gene test, and who should consider it? (ما هو فحص جين ATP13A2 ومن يجب أن يفكر فيه؟)
The ATP13A2 (PARK9) Genetic Test detects disease-causing mutations in patients with early-onset parkinsonism or suspected Kufor-Rakeb syndrome for accurate diagnosis and family counseling.
يكتشف فحص الحمض النووي ATP13A2 (PARK9) الطفرات الممرضة لدى المرضى المصابين بداء باركنسون المبكر أو متلازمة كوفور-ركيب المشتبه بها لتأكيد التشخيص والاستشارة الوراثية العائلية.
2. How accurate is the NGS technique, and what does the 3–4 week turnaround mean? (ما مدى دقة تقنية NGS وماذا تعني فترة النتائج البالغة 3–4 أسابيع؟)
Our ISO-certified NGS test offers 99.9% analytical sensitivity for single nucleotide variants and copy number changes, with results delivered in 3–4 weeks from sample receipt to final report.
يوفر فحص NGS الحاصل على شهادة ISO حساسية تحليلية بنسبة 99.9% لاكتشاف الطفرات النقطية والتغيرات في عدد النسخ، مع إصدار النتائج خلال 3–4 أسابيع من استلام العينة.
3. Is home sample collection available, and does insurance cover this genetic? (هل تتوفر خدمة سحب العينة منزلياً وهل يغطي التأمين هذا الفحص؟)
Yes, VIP home phlebotomy is offered across all UAE emirates with cold-chain handling, and we provide direct insurance billing verification through WhatsApp at +971 54 548 8731.
نعم، نوفر خدمة سحب الدم المنزلية في جميع إمارات الدولة مع النقل المبرد، ونقدم خدمة التحقق المباشر من تغطية التأمين عبر واتساب على الرقم 5488731 54 971+.
UAE Laboratory License: 9834453 | Support: +971 54 548 8731 | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Legal Compliance: Federal Decree-Law No. 41 of 2024 (Personal Data Protection, Art. 87), UAE CDS Law 2026 (Minors), DHA/MOHAP regulations. Genetic counseling session mandatory prior to testing.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians